Abstract
Antibody-induced demyelination is an important component of pathology in multiple sclerosis. In particular, antibodies to myelin oligodendrocyte glycoprotein (MOG) are elevated in multiple sclerosis patients, and they have been implicated as mediators of demyelination. We have shown previously that antibody cross-linking of MOG in oligodendrocytes results in the repartitioning of MOG into glycosphingolipid-cholesterol membrane microdomains ("lipid rafts"), followed by changes in the phosphorylation of specific proteins, including dephosphorylation of beta-tubulin and the beta subunit of the trimeric G protein and culminating in rapid and dramatic morphological alterations. In order to further elucidate the mechanism of anti-MOG-mediated demyelination, we have carried out a proteomic analysis to identify the set of proteins for which the phosphorylation states or expression levels are altered upon anti-MOG treatment. We demonstrate that treatment of oligodendrocytes with anti-MOG alone leads to an increase in calcium influx and activation of the MAPK/Akt pathways that is independent of MOG repartitioning. However, further cross-linking of anti-MOG.MOG complexes with a secondary anti-IgG results in the lipid raft-dependent phosphorylation of specific proteins related to cellular stress response and cytoskeletal stability. Oligodendrocyte survival is not compromised by these treatments. We discuss the possible significance of the anti-MOG-induced signaling cascade in relation to the initial steps of MOG-mediated demyelination.
Highlights
Antibody-induced demyelination is an important component of pathology in multiple sclerosis
We demonstrate that treatment of oligodendrocytes with anti-myelin oligodendrocyte glycoprotein (MOG) alone leads to an increase in calcium influx and activation of the mitogen-activated protein kinase (MAPK)/Akt pathways that is independent of MOG repartitioning
Treatment with anti-MOG alone was ineffective at inducing MOG repartitioning or changes in cell morphology [14]; these effects were confirmed in this study, even when treatment with anti-MOG alone was extended to 60 min (Fig. 1A)
Summary
Antibodies—Antibodies were obtained as follows: mouse monoclonal anti-MOG University of Aberdeen, UK); anti-myelin-associated glycoprotein (MAG) 513mAb National Institutes of Health, Bethesda, MD); anti-CRMP-2 Strittmatter, Yale University, New Haven, CT); anti-EF-2 Yale University); anti-G, -HSC70, -Fyn, -enolase, and -HSP90 ␣/ (Santa Cruz Biotechnology, Inc., Santa Cruz, CA); anti--actin,.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have